ArticleEquine veterinary journal2025
Treatment outcomes for equine osteoarthritis with mesenchymal stromal cells and hyaluronic acid.
Article in Equine veterinary journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Cord blood mesenchymal stromal cells combined with hyaluronic acid show symptom-modifying and potential disease-modifying effects in an equine osteoarthritis fetlock chip model.Frontiers in veterinary science · 2026Article
- Case Report: Equine allogeneic umbilical cord blood mesenchymal stromal cells (CB-MSC) as adjunctive therapy in a foal with septic arthritis and osteomyelitis.Frontiers in veterinary science · 2026Article
- Treatment outcomes for equine osteoarthritis with mesenchymal stromal cells and hyaluronic acid.Equine veterinary journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundMesenchymal stromal cells (MSCs) are widely used to treat osteoarthritis (OA). Optimising dose, timing, and safety while comparing efficacy with standard therapies like hyaluronic acid (HA) is essential for their standardisation.
objectivesTo assess the safety and efficacy of equine umbilical cord-derived (eCB) MSCs in client-owned horses with fetlock or carpus OA. STUDY
designProspective single-blinded randomised clinical study.
methodsHorses diagnosed with fetlock or carpus OA via intra-articular (IA) anaesthesia were randomly assigned to receive either 10 or 20 million eCB-MSCs in HA or 3 mL of HA alone (control). Subjective lameness examinations were performed at baseline, 3 weeks, and 6 weeks post-treatment. Adverse reactions were evaluated 24-72 h post-injection. Follow-up surveys were sent to owners at 18 weeks.
resultsTwenty-seven client-owned horses were enrolled. No significant adverse reactions occurred. Lameness outcomes did not differ significantly between treatment groups at 3 or 6 weeks (p > 0.05), though all groups showed improvement over time (p < 0.05). Median lameness change at 6 weeks was -1.5 (0.5) grades for HA, -2.0 (1.0) for 10-MSC + HA, and -2.0 (1.0) for 20-MSC + HA. Although return-to-work rates were not significantly different (p > 0.05), both MSC + HA groups had higher return rates to the same or higher work levels than HA-only (8 out of 9, 7 out of 9, and 5 out of 9, respectively). MAIN LIMITATIONS: Small sample size.
conclusionsThe study aimed to assess MSC treatment safety and efficacy. Higher return-to-exercise rates were expected in the MSC groups at 18 weeks, but unexpectedly high rates in the HA group may have led to underpowering. A post hoc calculation suggests 30 horses per group would be needed to detect significant differences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.